Equillium, Inc. EQ
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -9.68%
- 1 year
- -2.78%
- Market cap
- 109.71M
- Revenue (ttm)
- 42.62M
- Profit margin
- -19.51%
- EPS (ttm)
- -0.14
- Shares out
- 35.43M
- Forward P/E
- -0.47
- YTD return
- -9.68%
- 1-year return
- -2.78%
- Volume
- 194.70K
- Avg volume
- 566.07K
- Open
- 1.49
- Previous close
- 1.41
- Day's range
- 1.35 – 1.52
- 52-week range
- 0.76 – 3.54
- Beta
- 1.83
- Price target
- 3.33 (+138.1%)
- Earnings date
- Aug 8, 2024
2Y +0.66 (+89.19%)
Key statistics
- Enterprise value
- -8.45M
- PEG ratio
- 0.00
- Price / sales
- 0.50
- Price / book
- 0.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 51.80%
- Free cash flow
- -6.72M
- Total cash
- 33.30M
- Total debt
- 609.00K
- Return on equity
- -33.67%
- Short % of float
- 0.54%
- 50-day average
- 0.8356
- 200-day average
- 1.15
Analyst view
- Target (low)
- 2.00
- Target (mean)
- 3.33
- Target (high)
- 5.00
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.26.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.07 | 0.00 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.15 | 0.01 | +0.16 | +106.67% |
| Aug 8, 2024 | Jun 1, 2024 | -0.15 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.17 | -0.08 | +0.09 | +52.94% |
| May 9, 2024 | Mar 1, 2024 | -0.17 | — | — | — |
| Mar 25, 2024 | Dec 1, 2023 | -0.17 | -0.07 | +0.10 | +58.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 1, 2024 | Jones Trading | down | Buy | Hold |
| Aug 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 2, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 26, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- equilliumbio.com
News
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6 
Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20 - Leerink Partners Upgrades Equillium to Outperform, Raises Price Target to $6
- 12 Health Care Stocks Moving In Friday's After-Market Session
Equillium Q1 EPS $(0.06) Misses $(0.05) Estimate 
B. Riley Securities Initiates Coverage On Equillium with Buy Rating, Announces Price Target of $6 
Raymond James Initiates Coverage On Equillium with Strong Buy Rating, Announces Price Target of $6
Your note
Sign in to keep a note on EQ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KEYES JASON A | Chief Financial Officer | Sale | Nov 13, 2024 | 0 |
| ROTHMAN JOEL | Officer | Stock Award(Grant) | Dec 7, 2023 | 58,150 |
| TOM PENNY | Officer | Sale | Oct 27, 2024 | 6,533 |
| ZEDELMAYER CHRISTINE | Chief Operating Officer | Sale | Oct 27, 2024 | 135,246 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Decheng Capital LLC | 12.55% | 4,447,308 | 2.66M | Sep 29, 2024 |
| Vanguard Group Inc | 2.38% | 841,948 | 503.48K | Sep 29, 2024 |
| Cota Capital Management, Llc | 1.59% | 562,278 | 336.24K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.91% | 321,173 | 192.06K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.58% | 204,385 | 122.22K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 0.31% | 108,691 | 65.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.61% | 570,835 | 341.36K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.70% | 247,430 | 147.96K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.29% | 104,381 | 62.42K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 35,240 | 21.07K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.10% | 33,945 | 20.30K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 24,554 | 14.68K | Oct 30, 2024 |